Felicia Y T Yap

Summary

Country: Australia

Publications

  1. ncbi request reprint Advanced glycation end products as environmental risk factors for the development of type 1 diabetes
    Felicia Y T Yap
    BakerIDI Diabetes and Heart Institute, Melbourne, Victoria, Australia
    Curr Drug Targets 13:526-40. 2012
  2. pmc Advanced glycation end products are direct modulators of β-cell function
    Melinda T Coughlan
    Division of Diabetes Complications, Diabetes and Metabolism Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Diabetes 60:2523-32. 2011
  3. doi request reprint Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion
    Andrew L Siebel
    Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Circ Res 113:167-75. 2013
  4. ncbi request reprint Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway
    Vicki Thallas-Bonke
    JDRF Albert Einstein Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Medical Research Institute, P O Box 6492, St Kilda Rd, Central, Melbourne, Victoria, Australia
    Diabetes 57:460-9. 2008

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Advanced glycation end products as environmental risk factors for the development of type 1 diabetes
    Felicia Y T Yap
    BakerIDI Diabetes and Heart Institute, Melbourne, Victoria, Australia
    Curr Drug Targets 13:526-40. 2012
    ....
  2. pmc Advanced glycation end products are direct modulators of β-cell function
    Melinda T Coughlan
    Division of Diabetes Complications, Diabetes and Metabolism Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Diabetes 60:2523-32. 2011
    ..Excess accumulation of advanced glycation end products (AGEs) contributes to aging and chronic diseases. We aimed to obtain evidence that exposure to AGEs plays a role in the development of type 1 diabetes (T1D)...
  3. doi request reprint Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion
    Andrew L Siebel
    Baker IDI Heart and Diabetes Institute, Melbourne, Australia
    Circ Res 113:167-75. 2013
    ..High-density lipoprotein cholesterol elevation via cholesteryl ester transfer protein (CETP) inhibition represents a novel therapy for atherosclerosis, which also may have relevance for type 2 diabetes mellitus...
  4. ncbi request reprint Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway
    Vicki Thallas-Bonke
    JDRF Albert Einstein Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Medical Research Institute, P O Box 6492, St Kilda Rd, Central, Melbourne, Victoria, Australia
    Diabetes 57:460-9. 2008
    ..Since NADPH oxidase activation is closely linked to other putative pathways, its interaction with changes in protein kinase C (PKC) and increased advanced glycation was examined...